Search Results - "Chalasani, P"

ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury by Chalasani, Naga P., Maddur, Haripriya, Russo, Mark W., Wong, Robert J., Reddy, K. Rajender

“…Idiosyncratic drug-induced liver injury (DILI) is common in gastroenterology and hepatology practices, and it can have multiple presentations, ranging from…”
Get full text

Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis by Younossi, Zobair M., Loomba, Rohit, Anstee, Quentin M., Rinella, Mary E., Bugianesi, Elisabetta, Marchesini, Giulio, Neuschwander‐Tetri, Brent A., Serfaty, Lawrence, Negro, Francesco, Caldwell, Stephen H., Ratziu, Vlad, Corey, Kathleen E., Friedman, Scott L., Abdelmalek, Manal F., Harrison, Stephen A., Sanyal, Arun J., Lavine, Joel E., Mathurin, Philippe, Charlton, Michael R., Goodman, Zachary D., Chalasani, Naga P., Kowdley, Kris V., George, Jacob, Lindor, Keith

“…Nonalcoholic fatty liver disease (NAFLD) is a spectrum comprised of isolated steatosis, nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis…”
Get full text

Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis by Younossi, Zobair M., Loomba, Rohit, Rinella, Mary E., Bugianesi, Elisabetta, Marchesini, Giulio, Neuschwander‐Tetri, Brent A., Serfaty, Lawrence, Negro, Francesco, Caldwell, Stephen H., Ratziu, Vlad, Corey, Kathleen E., Friedman, Scott L., Abdelmalek, Manal F., Harrison, Stephen A., Sanyal, Arun J., Lavine, Joel E., Mathurin, Philippe, Charlton, Michael R., Chalasani, Naga P., Anstee, Quentin M., Kowdley, Kris V., George, Jacob, Goodman, Zachary D., Lindor, Keith

“…Nonalcoholic fatty liver disease (NAFLD) and its progressive form non‐alcoholic steatohepatitis (NASH), are rapidly becoming among the top causes of cirrhosis,…”
Get full text

A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma by Chalasani, Naga P., Ramasubramanian, Tiruvidaimarudur S., Bhattacharya, Abhik, Olson, Marilyn C., Edwards V, David K., Roberts, Lewis R., Kisiel, John B., Reddy, K. Rajender, Lidgard, Graham P., Johnson, Scott C., Bruinsma, Janelle J.

“…Hepatocellular carcinoma (HCC) can be treated effectively if detected at an early stage. Recommended surveillance strategies for at-risk patients include…”
Get full text

Hepatic histological findings in suspected drug‐induced liver injury: Systematic evaluation and clinical associations by Kleiner, David E., Chalasani, Naga P., Lee, William M., Fontana, Robert J., Bonkovsky, Herbert L., Watkins, Paul B., Hayashi, Paul H., Davern, Timothy J., Navarro, Victor, Reddy, Rajender, Talwalkar, Jayant A., Stolz, Andrew, Gu, Jiezhun, Barnhart, Huiman, Hoofnagle, Jay H.

“…Drug‐induced liver injury (DILI) is considered to be a diagnosis of exclusion. Liver biopsy may contribute to diagnostic accuracy, but the histological…”
Get full text

The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis by Puri, Puneet, Liangpunsakul, Suthat, Christensen, Jeffrey E., Shah, Vijay H., Kamath, Patrick S., Gores, Gregory J., Walker, Susan, Comerford, Megan, Katz, Barry, Borst, Andrew, Yu, Qigui, Kumar, Divya P., Mirshahi, Faridoddin, Radaeva, Svetlana, Chalasani, Naga P., Crabb, David W., Sanyal, Arun J.

“…Intestinal dysbiosis is implicated in alcoholic hepatitis (AH). However, changes in the circulating microbiome, its association with the presence and severity…”
Get full text

Death and liver transplantation within 2 years of onset of drug‐induced liver injury by Hayashi, Paul H., Rockey, Don C., Fontana, Robert J., Tillmann, Hans L., Kaplowitz, Neil, Barnhart, Huiman X., Gu, Jiezhan, Chalasani, Naga P., Reddy, K. Rajender, Sherker, Averell H., Hoofnagle, Jay H.

“…Drug‐induced liver injury (DILI) is an important cause of death and indication for liver transplantation (fatality). The role of DILI in these fatalities is…”
Get full text

IL‐12/Th1 and IL‐23/Th17 biliary microenvironment in primary biliary cirrhosis: Implications for therapy by Yang, Chen‐Yen, Ma, Xiong, Tsuneyama, Koichi, Huang, Shanshan, Takahashi, Toru, Chalasani, Naga P., Bowlus, Christopher L., Yang, Guo‐Xiang, Leung, Patrick S.C., Ansari, Aftab A., Wu, Linda, Coppel, Ross L., Gershwin, M. Eric

“…The interleukin (IL)‐12/IL‐23‐mediated Th1/Th17 signaling pathway has been associated with the etiopathogenesis of primary biliary cirrhosis (PBC). To address…”
Get full text

Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis by Sehrawat, Tejasav S., Arab, Juan P., Liu, Mengfei, Amrollahi, Pouya, Wan, Meihua, Fan, Jia, Nakao, Yasuhiko, Pose, Elisa, Navarro‐Corcuera, Amaia, Dasgupta, Debanjali, Liao, Chieh‐Yu, He, Li, Mauer, Amy S., Avitabile, Emma, Ventura‐Cots, Meritxell, Bataller, Ramon A., Sanyal, Arun J., Chalasani, Naga P., Heimbach, Julie K., Watt, Kymberly D., Gores, Gregory J., Gines, Pere, Kamath, Patrick S., Simonetto, Douglas A., Hu, Tony Y., Shah, Vijay H., Malhi, Harmeet

“…Background and Aims Alcoholic hepatitis (AH) is diagnosed by clinical criteria, although several objective scores facilitate risk stratification. Extracellular…”
Get full text

Occult liver disease: A multinational perspective by Vidal-Cevallos, Paulina, Flores-García, Nayelli, Chávez-Tapia, Norberto C., Chalasani, Naga P.

“…Occult liver disease refers to the presence of unrecognized chronic liver disease and cirrhosis. Liver disease is currently the eleventh cause of death…”
Get full text

ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury by Chalasani, Naga P, Hayashi, Paul H, Bonkovsky, Herbert L, Navarro, Victor J, Lee, William M, Fontana, Robert J

Get full text

Obesity associated molecular forms of C-reactive protein in human by Asztalos, Bela F, Horan, Michael S, Horvath, Katalin V, McDermott, Ann Y, Chalasani, Naga P, Schaefer, Ernst J

“…To describe novel C-reactive protein (CRP) molecular forms (mf) in human plasma. Five novel CRP-mfs, disctinct from the previously described native (nCRP) and…”
Get full text

GDF8 Contributes to Liver Fibrogenesis and Concomitant Skeletal Muscle Wasting by Culver, Alexander, Hamang, Matthew, Wang, Yan, Jiang, Huaizhou, Yanum, Jennifer, White, Emily, Gawrieh, Samer, Vuppalanchi, Raj K, Chalasani, Naga P, Dai, Guoli, Yaden, Benjamin C

“…Patients with end-stage liver disease exhibit progressive skeletal muscle atrophy, highlighting a negative crosstalk between the injured liver and muscle. Our…”
Get full text

Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review by Stahl, Eric P, Dhindsa, Devinder S, Lee, Suegene K, Sandesara, Pratik B, Chalasani, Naga P, Sperling, Laurence S

“…Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) are both manifestations of end-organ damage of the metabolic syndrome. Through…”
Get full text

ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury by Chalasani, Naga P, Hayashi, Paul H, Bonkovsky, Herbert L, Navarro, Victor J, Lee, William M, Fontana, Robert J

“…Idiosyncratic drug-induced liver injury (DILI) is a rare adverse drug reaction and it can lead to jaundice, liver failure, or even death. Antimicrobials and…”
Get full text

Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia by Crabb, David W, Bataller, Ramon, Chalasani, Naga P, Kamath, Patrick S, Lucey, Michael, Mathurin, Philippe, McClain, Craig, McCullough, Arthur, Mitchell, Mack C, Morgan, Timothy R, Nagy, Laura, Radaeva, Svetlana, Sanyal, Arun, Shah, Vijay, Szabo, Gyongyi

Get full text

Nonalcoholic Fatty Liver Disease and the Heart by Stahl, Eric P., Dhindsa, Devinder S., Lee, Suegene K., Sandesara, Pratik B., Chalasani, Naga P., Sperling, Laurence S.

“…Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) are both manifestations of end-organ damage of the metabolic syndrome. Through…”
Get full text

Nonalcoholic Fatty Liver Disease in Latinos by Saab, Sammy, Manne, Vignan, Nieto, Jose, Schwimmer, Jeffrey B, Chalasani, Naga P

“…Nonalcoholic fatty liver disease (NAFLD) is a serious public health concern that affects almost one third of the US population. The prevalence of NAFLD varies…”
Get full text

Autoimmune Hepatitis Triggered by Statins by Alla, Vamsee, Abraham, Joseph, Siddiqui, Junaid, Raina, Dimple, Wu, George Y, Chalasani, Naga P, Bonkovsky, Herbert L

“…Although the cause of autoimmune hepatitis (AIH) is unknown, drugs are believed to be potential triggers in some patients. In isolated case reports, statins…”
Get full text

Review article: the safety of anticoagulants and antiplatelet agents in patients with cirrhosis by Ma, Jiayi, Chalasani, Naga P., Schwantes‐An, Linus, Björnsson, Einar Stefán

“…Summary Patients with cirrhosis were long thought to be coagulopathic. However, this paradigm has changed in recent years and currently, cirrhosis is…”
Get full text